DNA

Europe Laboratory Information Management System (LIMS) Market Insights Report 2023-2028: Rise in Remote Access Needs Boosts Cloud-Based LIMS Adoption Across Europe

Retrieved on: 
Friday, February 16, 2024

DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 16, 2024 /PRNewswire/ -- The "Europe Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report offers market size & forecast data for the Europe laboratory information management system (LIMS) market.
  • The laboratory information management system (LIMS) is a software-based laboratory and information management system which supports modern laboratory operations.
  • Who are the key players in the Europe laboratory information management system (LIMS) market?

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

BIZCLIK MEDIA LAUNCHES FEBRUARY EDITION OF TECHNOLOGY MAGAZINE AND DATA CENTRE MAGAZINE

Retrieved on: 
Thursday, February 15, 2024

LONDON, Feb. 15, 2024 /PRNewswire/ -- BizClik, the UK's fastest-growing publishing company, has published the latest editions of Technology Magazine and Data Centre Magazine. These publications are highly regarded within the Tech and Cloud sectors for their in-depth reports and interviews with prominent figures in the respective industries.

Key Points: 
  • The February editions of Technology Magazine and Data Centre Magazine include interviews with leading experts and executives from Microsoft and Data Castle.
  • LONDON, Feb. 15, 2024 /PRNewswire/ -- BizClik, the UK's fastest-growing publishing company, has published the latest editions of Technology Magazine and Data Centre Magazine .
  • The other word that's completely underpinning that of course, is data, data, data."
  • Read the edition here and visit Technology Magazine and Data Centre Magazine for daily news and analysis of the ever-changing technology industry.

BIZCLIK MEDIA LAUNCHES FEBRUARY EDITION OF TECHNOLOGY MAGAZINE AND DATA CENTRE MAGAZINE

Retrieved on: 
Thursday, February 15, 2024

LONDON, Feb. 15, 2024 /PRNewswire/ -- BizClik, the UK's fastest-growing publishing company, has published the latest editions of Technology Magazine and Data Centre Magazine. These publications are highly regarded within the Tech and Cloud sectors for their in-depth reports and interviews with prominent figures in the respective industries.

Key Points: 
  • The February editions of Technology Magazine and Data Centre Magazine include interviews with leading experts and executives from Microsoft and Data Castle.
  • LONDON, Feb. 15, 2024 /PRNewswire/ -- BizClik, the UK's fastest-growing publishing company, has published the latest editions of Technology Magazine and Data Centre Magazine .
  • The other word that's completely underpinning that of course, is data, data, data."
  • Read the edition here and visit Technology Magazine and Data Centre Magazine for daily news and analysis of the ever-changing technology industry.

Asure Partners with Key Benefit Administrators to Offer Proactive Health Management Plan (PHMP) to Clients

Retrieved on: 
Thursday, February 15, 2024

This collaboration aims to deliver the innovative Proactive Health Management Plan (PHMP) to Asure’s client base, enhancing their access to proven, patented, and comprehensive population health programs and services.

Key Points: 
  • This collaboration aims to deliver the innovative Proactive Health Management Plan (PHMP) to Asure’s client base, enhancing their access to proven, patented, and comprehensive population health programs and services.
  • The partnership between Asure and Key Benefit Administrators is a milestone in the effort to transform employee health and reduce costs for both employer and employee.
  • Larry Dust, CEO of Key Benefit Administrators, expressed his enthusiasm about the partnership, stating, “We are excited to partner with Asure to bring PHMP to a wider audience.
  • Partnering with Key Benefit Administrators to offer PHMP is a testament to our commitment to innovation and excellence in the HCM space.

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

Retrieved on: 
Thursday, February 15, 2024

A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.

Key Points: 
  • A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.
  • Prostate cancer is the most frequently diagnosed non-skin cancer globally, and as such, it is a problem that affects the entire human population.
  • To understand the likelihood of an individual or population developing prostate cancer, researchers create what is known as a Genetic Risk Score (GRS).
  • This work was centered around a desire to understand the genetic makeup that increases risks for diseases like prostate cancer.

Getlabs to Add GRAIL's GalleriⓇ Multi-Cancer Early Detection Test to Suite of At-Home Diagnostic Services

Retrieved on: 
Thursday, February 15, 2024

MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.

Key Points: 
  • MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.
  • The Galleri test is a significant advancement in multi-cancer early detection screening.
  • "By leveraging our expertise in at-home diagnostic collections, we can greatly expand access to critical cancer screening services.
  • Our partnership with GRAIL represents a step forward in saving lives through early cancer detection."

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”